{
    "ticker": "VRCA",
    "name": "Viracta Therapeutics, Inc.",
    "description": "Viracta Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for cancer patients. Founded in 2014, the company is dedicated to addressing the urgent medical need for effective treatments against virus-associated cancers, particularly those related to Epstein-Barr Virus (EBV). Viracta's lead candidate, VRCA006, is a novel therapy designed to target and eliminate EBV-infected cancer cells, leveraging the unique biology of the virus to selectively kill malignant cells while sparing healthy tissue. The company is also exploring combination therapies that enhance the efficacy of its lead product, aiming to improve patient outcomes in a variety of hematologic malignancies and solid tumors. Viracta is committed to advancing its clinical programs through rigorous scientific research and collaboration with leading medical institutions. The company's mission is to transform the treatment landscape for patients with virus-associated cancers, providing hope for those who have limited therapeutic options. As of now, Viracta is actively conducting clinical trials and working to bring its breakthrough therapies to market, with a vision of making a significant impact on patient lives.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2014",
    "website": "https://www.viracta.com",
    "ceo": "James A. C. E. H. C. H. McCully",
    "social_media": {
        "twitter": "https://twitter.com/Viracta",
        "linkedin": "https://www.linkedin.com/company/viracta-therapeutics"
    },
    "investor_relations": "https://ir.viracta.com",
    "key_executives": [
        {
            "name": "James A. C. E. H. C. H. McCully",
            "position": "CEO"
        },
        {
            "name": "Gina D. M. A. L. C. A. C. C. B. H. C. McCully",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapies",
            "products": [
                "VRCA006"
            ]
        }
    ],
    "seo": {
        "meta_title": "Viracta Therapeutics, Inc. | Innovative Cancer Treatments",
        "meta_description": "Explore Viracta Therapeutics, Inc., a biotechnology company developing therapies for virus-associated cancers. Learn about our mission and pipeline.",
        "keywords": [
            "Viracta",
            "Biotechnology",
            "Cancer Treatments",
            "Epstein-Barr Virus",
            "Oncology",
            "VRCA006"
        ]
    },
    "faq": [
        {
            "question": "What is Viracta Therapeutics known for?",
            "answer": "Viracta Therapeutics is known for developing innovative therapies for cancer, specifically targeting virus-associated cancers."
        },
        {
            "question": "Who is the CEO of Viracta Therapeutics?",
            "answer": "James A. C. E. H. C. H. McCully is the CEO of Viracta Therapeutics, Inc."
        },
        {
            "question": "Where is Viracta Therapeutics headquartered?",
            "answer": "Viracta Therapeutics is headquartered in San Diego, California, USA."
        },
        {
            "question": "What is Viracta's lead product?",
            "answer": "Viracta's lead product is VRCA006, a therapy targeting EBV-infected cancer cells."
        },
        {
            "question": "When was Viracta Therapeutics founded?",
            "answer": "Viracta Therapeutics was founded in 2014."
        }
    ],
    "competitors": [
        "CRMD",
        "KPTI",
        "IMMP",
        "CLVS"
    ],
    "related_stocks": [
        "AAPL",
        "AMGN",
        "GILD",
        "MRNA"
    ]
}